prostate cancer treatment Articles
-
Antibody-Drug Conjugates For The Treatment of Prostate Cancer
Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). STEAP1, TROP2, PSMA, CD46, and B7-H3 are currently ...
-
Low-dose irradiation for controlling prostate cancer
Prostate cancer is the second most commonly diagnosed cancer among North American men and the second leading cause of death in those aged 65 and over. The US Cancer Society recommends testing those over 50 years of age who are expected to live at least for 10 years, even though the ability of early detection to decrease prostate cancer mortality has not been demonstrated. A controversy exists ...
-
Nanostics Receives CE Mark for its ClarityDX Prostate Test to Detect Clinically Significant Prostate Cancer
Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark. A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries. The ClarityDX Prostate® test provides patients ...
-
Dosimetry analysis of two new design 103 Pd interstitial brachytherapy sources
With increased demand for low 103 Pd (palladium) seed sources, to treat prostate and eye cancers, new sources have been designed and introduced. This paper presents the two new palladium brachytherapy sources, IR03- 103 Pd and IR04- 103 Pd that have been developed at Agricultural, Medical & Industrial Research School . The dosimetric parameters, such as the dose rate constant Λ , ...
-
B7-H3: Broad Prospects of Emerging Tumor Immunotherapy Targets
Recently, in the renowned academic journal Nature Medicine, the Kimmel Cancer Center at Johns Hopkins University published Phase 2 clinical results regarding enoblituzumab, a monoclonal antibody targeting B7-H3, for the treatment of prostate cancer. The results demonstrate that enoblituzumab can successfully induce the body's anti-cancer activity, showing favorable therapeutic efficacy and safety ...
-
Movember Together: How Paige, University of Oxford, and Prostate Cancer UK Are Working to Change the Prostate Cancer Experience
Movember is an annual initiative where men from around the globe grow mustaches to raise awareness for men’s health causes, including mental health and suicide prevention, testicular cancer, and prostate cancer. Through events, fundraising, and using mustaches as a light-hearted starting point for important conversations, the movement supports men in taking charge of their health to live ...
-
Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site
Summary Nanostics' clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked research institute in the Northeast US will now partner with Nanostics' by recruiting patients for the clinical validation study This partnership will ...
-
Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer
Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform. The study is supported in part by the Alberta Innovates AICE-Concepts Program with a ...
-
Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies. The clinical study recruited men from two sites in Alberta, Canada, and one site ...
-
FDA Approved Peptide Drugs in the First Half of 2023
The FDA's Center for Drug Evaluation and Research (CDER) regulatory approval of a total of 26 NME (New Molecular Entity) drugs in the first half of 2023. It is worth noting that the 26 drugs approved include 4 peptide drugs, accounting for 15% of the total. In the past 2022, the FDA has approved only three peptide drugs: Tirzepatide, Lutetium 177Lu Vipivotide Tetraxetan and Terlipressin, of which ...
-
California Prop65 list
1. Tetrahydrocannabinol (THC) Tetrahydrocannabinol (THC) is an active ingredient in Nabiximols, a specific extract of Cannabis that was approved as a botanical drug in the United Kingdom since 2010 as a mouth spray for people with multiple sclerosis to reduce neuropathic pain, spasticity, overactive bladder, and other symptoms. Nabiximols (as Sativex) is available as a prescription drug in ...
-
How Has the COVID-19 Pandemic Affected Prostate Cancer Care?
#CancelEverything On March 11, 2020, the World Health Organization (WHO) declared the coronavirus 2019 disease (COVID-19) a global pandemic. Its impact left the world uncertain about health, politics and the economy. The first wave caused a major disruption to health services, exacerbating concerns of patient and physician safety and resource availability. On trend with the “cancel ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you